Publication Date: October 5, 2025
A new clinical study has been announced, investigating the therapeutic potential of two different low-intensity red light devices for the management of myopia. The research, led by Ruihua Wei in collaboration with Tianjin Medical University Eye Hospital, aims to assess the efficacy and safety of these devices when used at varying frequencies. Although recruitment for participants has not yet begun, the study promises advancements in evidence-based myopia treatment options.
What is the objective of the study?
The primary goal of this study is to evaluate the effectiveness of repeated exposure to low-intensity red light for individuals with myopia. Myopia, a common refractive error, is progressively impacting populations globally, particularly children and young adults. The research will explore whether different devices and usage frequencies can achieve meaningful therapeutic benefits in slowing or potentially reversing myopia progression.
What devices are being tested?
The study utilizes two distinct red light therapy devices:
- Eyerising RS-200-2A: A device designed specifically for ocular health interventions.
- Airdoc Sky-n1201: Another innovative solution targeting myopia management.
Both devices will be monitored for their performance, safety profiles, and potential compliance benefits under real-world conditions. According to the developers, their systems aim to deliver consistent low-intensity red light, a wavelength previously studied for its potential impact on eye health.
Who is conducting the research, and what is the study status?
This clinical trial is sponsored by Ruihua Wei and Tianjin Medical University Eye Hospital, underscoring their ongoing commitment to addressing significant challenges in ophthalmology. The study is registered under ClinicalTrials.gov identifier NCT07186088. As of the latest update, recruitment has not yet started. Individuals interested in participating or tracking the study can monitor updates via this official registry link.
FAQ
- 1. What is low-intensity red light therapy?
- It is a treatment modality that uses specific wavelengths of red light to stimulate biological processes, including potential benefits for eye health.
- 2. Can these devices cure myopia?
- These devices are under investigation for their ability to manage or slow myopia progression, not to provide a definitive cure.
- 3. What is the significance of ClinicalTrials.gov registration?
- It ensures transparency and accessibility of study protocols for researchers, practitioners, and the public.
Conclusion
This upcoming research represents a significant opportunity to refine therapeutic strategies for myopia management. By exploring novel red light technologies and usage patterns, the study aims to deliver actionable evidence for clinicians and medical device developers alike. Stay tuned for updates as this trial progresses into recruitment and evaluation phases.
Disclaimer
This article aims to inform clinical, regulatory, and quality teams about a new study. It does not constitute legal or medical advice, and stakeholders should consult official documentation before decisions.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07186088?term=medical+device